Search Result

Results for "

cyclin E

" in MCE Product Catalog:

By Targets:	CDK (26) ADC Cytotoxin (1) Akt (1) Antibiotic (3) Apoptosis (13) Arp2/3 Complex (2) Arrestin (2) ATM/ATR (1) Autophagy (4) Bacterial (3) Carbonic Anhydrase (1) Caspase (1) CFTR (1) CXCR (3) DNA/RNA Synthesis (1) Elastase (1) Endogenous Metabolite (2) Enterovirus (1) ERK (2) Estrogen Receptor/ERR (1) Eukaryotic Initiation Factor (eIF) (1) Formyl Peptide Receptor (FPR) (1) Fungal (4) FXR (1) GHSR (1) GSK-3 (8) HCV (1) HIF/HIF Prolyl-Hydroxylase (2) HIV (1) IFNAR (1) Integrin (6) JAK (2) JNK (2) MEK (2) Melanocortin Receptor (1) Molecular Glues (3) NF-κB (1) Nuclear Factor of activated T Cells (NFAT) (1) Parasite (1) PD-1/PD-L1 (1) PKC (1) Reactive Oxygen Species (2) Somatostatin Receptor (5) STAT (1) Vasopressin Receptor (1)
By Research Areas:	Cancer (44) Endocrinology (3) Infection (11) Inflammation/Immunology (7) Metabolic Disease (6) Neurological Disease (7)

By Targets:

CDK (26)

ADC Cytotoxin (1)

Akt (1)

Antibiotic (3)

Apoptosis (13)

Arp2/3 Complex (2)

Arrestin (2)

ATM/ATR (1)

Autophagy (4)

Bacterial (3)

Carbonic Anhydrase (1)

Caspase (1)

CFTR (1)

CXCR (3)

DNA/RNA Synthesis (1)

Elastase (1)

Endogenous Metabolite (2)

Enterovirus (1)

ERK (2)

Estrogen Receptor/ERR (1)

Eukaryotic Initiation Factor (eIF) (1)

Formyl Peptide Receptor (FPR) (1)

Fungal (4)

FXR (1)

GHSR (1)

GSK-3 (8)

HCV (1)

HIF/HIF Prolyl-Hydroxylase (2)

HIV (1)

IFNAR (1)

Integrin (6)

JAK (2)

JNK (2)

MEK (2)

Melanocortin Receptor (1)

Molecular Glues (3)

NF-κB (1)

Nuclear Factor of activated T Cells (NFAT) (1)

Parasite (1)

PD-1/PD-L1 (1)

PKC (1)

Reactive Oxygen Species (2)

Somatostatin Receptor (5)

STAT (1)

Vasopressin Receptor (1)

By Research Areas:

Cancer (44)

Endocrinology (3)

Infection (11)

Inflammation/Immunology (7)

Metabolic Disease (6)

Neurological Disease (7)

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Targets Recommended: Cyclin G-associated Kinase (GAK) CDK

Cat. No.	Product Name	Target	Research Areas

HY-108359

Alsterpaullone 9-Nitropaullone; NSC 705701	CDK GSK-3 Apoptosis	Cancer
Alsterpaullone (9-Nitropaullone) is a potent CDK inhibitor, with IC₅₀s of 35 nM, 15 nM, 200 nM and 40 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E and CDK5/p35, respectively. Alsterpaullone also competes with ATP for binding to GSK-3alpha/GSK-3beta with IC₅₀s of both 4 nM. Alsterpaullone has antitumor activity, and possesses potential for the study in neurodegenerative and proliferative disorders. Alsterpaullone induces apoptosis in leukemia cell line.

HY-18299

Purvalanol B NG 95	CDK Parasite	Cancer Infection
Purvalanol B (NG 95) is a potent, selective, reversible and ATP-competitive inhibitor CDK, with IC₅₀s of 6 nM, 6 nM, 9 nM, 6 nM for cdc2-cyclin B, CDK2-cyclin A, CDK2-cyclin E and CDK5-p35, respectively. Purvalanol B shows selectivity for CDK over a range of other protein kinases (IC₅₀>1000 nM). Purvalanol B inhibits the growth a chloroquine-resistant strain of P. falciparum.

HY-12529

Ro-3306
CDK Apoptosis Cancer

Ro-3306 is a potent and selective inhibitor of CDK1, with K_is of 20 nM, 35 nM and 340 nM for CDK1, CDK1/cyclin B1 and CDK2/cyclin E, respectively.

Ro-3306	CDK Apoptosis	Cancer
Ro-3306 is a potent and selective inhibitor of CDK1, with K_is of 20 nM, 35 nM and 340 nM for CDK1, CDK1/cyclin B1 and CDK2/cyclin E, respectively.

HY-18299A

Purvalanol A NG-60	CDK Autophagy Apoptosis	Cancer
Purvalanol A is a potent CDK inhibitor, which inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with IC₅₀s of 4, 70, 35, 850, 75 nM, resepctively.

HY-10014

R547	CDK GSK-3 Apoptosis	Cancer
R547 is a potent, selective and orally active ATP-competitive CDK inhibitor, with K_is of 2 nM, 3 nM and 1 nM for CDK1/cyclin B, CDK2/cyclin E and CDK4/cyclin D1, respectively.

HY-111932

Indirubin-5-sulfonate	CDK GSK-3	Cancer
Indirubin-5-sulfonate is a cyclin-dependent kinase (CDK) inhibitor, with IC₅₀ values of 55 nM, 35 nM, 150 nM, 300 nM and 65 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK4/cyclin D1, and CDK5/p35, respectively. Indirubin-5-sulfonate also shows inhibitory activity against GSK-3β.

HY-114903

(E/Z)-BIO-acetoxime GSK-3 Inhibitor X	GSK-3 CDK	Cancer Metabolic Disease Neurological Disease
(E/Z)-BIO-acetoxime (GSK-3 Inhibitor X) is a potent and selective GSK-3α/β inhibitor, with an IC₅₀ of 10 nM. (E/Z)-BIO-acetoxime shows more than 200-flod selectivity over CDK5/p25, CDK2/cyclin A and CDK1/cyclin B (IC₅₀=2.4, 4.3, 63 μM).

HY-10424

Milciclib PHA-848125	CDK Autophagy	Cancer
Milciclib (PHA-848125) is a potent, ATP-competitive and dual inhibitor of CDK and Tropomyosin receptor kinase (TRK), with IC₅₀s of 45, 150, 160, 363, 398 nM and 53 nM for cyclin A/CDK2, cyclin H/CDK7, cyclin D1/CDK4, cyclin E/CDK2, cyclin B/CDK1 and TRKA, respectively.

HY-15504A

RGB-286638 free base	CDK GSK-3 MEK JAK	Cancer
RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, **cyclin E-CDK2*, cyclin* D1-CDK4, **cyclin E-CDK3, and p35-CDK5 with IC₅₀s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC₅₀**s of 3, 5, 50, and 54 nM.

HY-15504

RGB-286638	CDK GSK-3 MEK JAK	Cancer
RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, **cyclin E-CDK2*, cyclin* D1-CDK4, **cyclin E-CDK3, and p35-CDK5 with IC₅₀s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC₅₀**s of 3, 5, 50, and 54 nM.

HY-12843

Bohemine	CDK ERK	Cancer
Bohemine is a purine analogue and is a synthetic and selective CDK inhibitor with IC₅₀s of 4.6 μM, 83 μM, and 2.7 μM for Cdk2/cyclin E, Cdk2/cyclin A, and Cdk9/cyclin T1, respectively. Bohemine also inhibits ERK2 with an IC₅₀ of 52 μM and has less inhibitory effect on CDK1, CDK4 and CDK6. Bohemine has a broad spectrum anti-cancer activities.

HY-112371

(S)-CR8	CDK	Cancer
(S)-CR8 is the S-isomer of CR8. (S)-CR8 is a potent and selective CDK inhibitor with IC₅₀s of 0.060, 0.080, 0.11, 0.12, and 0.15 μM for CDK2/cyclin E, CDK2/cyclin A, CDK9/cyclin T, CDK5/p25, and CDK1/cyclin B, respectively. (S)-CR8 reduces SH-SY5Y cells survival (IC₅₀ 0.40 μM).

HY-N0417

Cucurbitacin E α-Elaterin; α-Elaterine	CDK Autophagy	Cancer
Cucurbitacin E is a natural compound which from Cucurbitaceae plants. Cucurbitacin E significantly suppresses the activity of the cyclin B1/CDC2 complex.

HY-12302

Kenpaullone 9-Bromopaullone; NSC-664704	CDK GSK-3	Cancer
Kenpaullone is a potent inhibitor of CDK1/cyclin B and GSK-3β, with IC₅₀s of 0.4 μM and 23 nM, and also inhibits CDK2/cyclin A, CDK2/cyclin E, and CDK5/p25 with IC₅₀s of 0.68 μM, 7.5 μM, 0.85 μM, respectively. Kenpaullone, a small molecule inhibitor of KLF4, reduces self-renewal of breast cancer stem cells and cell motility in vitro.

HY-139328

CDK12-IN-5	CDK	Cancer
CDK12-IN-5, a pyrazolotriazine, is a potent CDK12 inhibitor with an IC₅₀ of 23.9 nM at high ATP (2 mM). CDK12-IN-5 has no effect on CDK2/Cyclin E (IC₅₀=173 μM) and CDK9/Cyclin T1 (IC₅₀=127 μM) at high ATP (2 mM) (WO2021116178A1).

HY-W011428

Olomoucine	CDK	Others
Olomoucine is an ATP competitive inhibitor of CDKs. Olomoucine is a purine (HY-34431) derivative and inhibits CDC2/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E (both IC₅₀=7 µM), CDK/p35 kinase (IC₅₀=3 µM) and ERK1/p44 MAP kinase (IC₅₀=25 µM). Olomoucine regulates cell cycle and shows anti-melanin tumor activity.

HY-18340A

(R)-CR8 trihydrochloride CR8, (R)-Isomer trihydrochloride	Molecular Glues CDK Apoptosis	Cancer Neurological Disease
(R)-CR8 (CR8) trihydrochloride, a second-generation analog of Roscovitine, is a potent CDK1/2/5/7/9 inhibitor. (R)-CR8 trihydrochloride inhibits CDK1/cyclin B (IC₅₀=0.09 μM), CDK2/cyclin A (0.072 μM), CDK2/cyclin E (0.041 μM), CDK5/p25 (0.11 μM), CDK7/cyclin H (1.1 μM), CDK9/cyclin T (0.18 μM) and CK1δ/ε (0.4 μM). (R)-CR8 trihydrochloride induces apoptosis and has neuroprotective effect. (R)-CR8 trihydrochloride acts as a molecular glue degrader that depletes cyclin K.

HY-18340

(R)-CR8 CR8, (R)-Isomer	Molecular Glues CDK Apoptosis	Cancer Neurological Disease
(R)-CR8 (CR8), a second-generation analog of Roscovitine, is a potent CDK1/2/5/7/9 inhibitor. (R)-CR8 inhibits CDK1/cyclin B (IC₅₀=0.09 μM), CDK2/cyclin A (0.072 μM), CDK2/cyclin E (0.041 μM), CDK5/p25 (0.11 μM), CDK7/cyclin H (1.1 μM), CDK9/cyclin T (0.18 μM) and CK1δ/ε (0.4 μM). (R)-CR8 induces apoptosis and has neuroprotective effect. (R)-CR8 acts as a molecular glue degrader that depletes cyclin K.

HY-139329

CDK12-IN-6	CDK	Cancer
CDK12-IN-6, a pyrazolotriazine, is a potent CDK12 inhibitor with an IC₅₀ of 1.19 μM at high ATP (2 mM). CDK12-IN-6 has no effect on CDK2/Cyclin E (IC₅₀>20 μM) and CDK9/Cyclin T1 (IC₅₀>20 μM) at high ATP (2 mM) (WO2021116178A1).

HY-139327

CDK12-IN-4	CDK	Cancer
CDK12-IN-4, a pyrazolotriazine, is a potent CDK12 inhibitor with an IC₅₀ of 0.641 μM at high ATP (2 mM). CDK12-IN-4 has no effect on CDK2/Cyclin E (IC₅₀>20 μM) and CDK9/Cyclin T1 (IC₅₀>20 μM) at high ATP (2 mM) (WO2021116178A1).

HY-112363

Aloisine A RP107	CDK GSK-3 ERK JNK CFTR	Cancer Inflammation/Immunology
Aloisine A (RP107) is a a potent cyclin-dependent kinase (CDK) inhibitor with IC₅₀s of 0.15 μM, 0.12 μM, 0.4 μM, 0.16 μM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK5/p35, respectively. Aloisine A ininhibits GSK-3α (IC₅₀=0.5 µM) and GSK-3β (IC₅₀=1.5 µM). Aloisine A stimulates wild-type CFTR and mutated CFTR, with submicromolar affinity by a cAMP-independent mechanism. Aloisine A has the potential for CFTR-related diseases, including cystic fibrosis research.

HY-19831A

(Z)-4EGI-1	Eukaryotic Initiation Factor (eIF)	Cancer
(Z)-4EGI-1 is the Z-isomer of 4EGI-1 and is an inhibitor of eIF4E/eIF4G interaction and of translation initiation. (Z)-4EGI-1 effectively binds to eIF4E with an IC₅₀ of 43.5 μM and a K_d value of 8.74 μM. (Z)-4EGI-1 has anticancer activity.

HY-N6954

Garcinone C	ATM/ATR STAT CDK	Cancer
Garcinone C, a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia that is used as an anti-inflammatory, astringency and granulation-promoting medicine, and has potential cytotoxic effects on certain cancers. Garcinone C stimulates the expression levels of ATR and *4E-BP1, while efficiently inhibiting the expression levels of cyclin* B1, cyclin D1, cyclin E2, cdc2, Stat3 and CDK7. Garcinone C significantly inhibits cell viability of the human Nasopharyngeal carcinoma (NPC) cell lines CNE1, CNE2, HK1 and HONE1 in a time‑ and dose‑dependent manner.

HY-133537

Hygrolidin	Antibiotic Fungal ADC Cytotoxin	Cancer Infection
Hygrolidin is a 16-membered macrolide antibiotic produced by Streptomyces hygroscopicus D-1166. Hygrolidin has anti-fungus activity against Valsa ceratosperma. Hygrolidin induces p21 expression and abrogates cell cycle progression at G1 and S phases. Hygrolidin has antitumor activity.

HY-13650

Indisulam E 7070	Molecular Glues Carbonic Anhydrase	Cancer
Indisulam (E 7070) is a carbonic anhydrase inhibitor with anticancer activity. Indisulam (E 7070) is a sulfonamide agent that targets the G1 phase of the cell cycle. Indisulam (E 7070) causes a blockade in the G1/S transition through inhibition of the activation of both CDK2 and cyclin E. Indisulam (E 7070) targets splicing by inducing RBM39 degradation via recruitment to DCAF15.

HY-150641

CDK-IN-9	CDK Apoptosis DNA/RNA Synthesis	Cancer
CDK-IN-9 (compound 24) is a potent CDK inhibitor, also as a molecular glue inducing an interaction between CDK12 and DDB1, with an IC₅₀ values of 4 nM for CDK2/E. CDK-IN-9 leads to polyubiquitination of cyclin K and its subsequent degradation. CDK-IN-9 induce apoptosis through dephosphorylation of retinoblastoma protein and RNA polymerase II.

HY-126251

CDK9-IN-7	CDK Apoptosis	Cancer
CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor (IC₅₀=11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without obvious toxicity. CDK9-IN-7 induces NSCLC cell apoptosis, arrests the cell cycle in the G2 phase, and suppresses the stemness properties of NSCLC.

HY-11009

CGP60474	CDK PKC	Cancer
CGP60474, a highly potent anti-endotoxemic agent, is a potent cyclin-dependent kinase (CDK) inhibitor (IC₅₀ values are 26, 3, 4, 216, 10, 200 and 13 nM for CDK1/B, CDK2/E, CDK2/A, CDK4/D, CDK5/p25, CDK7/H and CDK9/T, respectively). CGP60474 is a selective and ATP-competitive PKC inhibitor.

HY-W019806

Lacto-N-fucopentaose I LNFP I	Endogenous Metabolite CDK Reactive Oxygen Species Apoptosis Enterovirus Bacterial	Infection Inflammation/Immunology
Lacto-N-fucopentaose I (LNFPI) is a human milk oligosaccharide (HMO), possessing antiviral and antibacterial activity. Lacto-N-fucopentaose I can reduce capsid protein VP1 to block virus adsorption, promote CDK2 and reduce cyclin E to recover cell cycle S phase block. Lacto-N-fucopentaose I inhibits ROS production and apoptosis in virus-infected cells. Lacto-N-fucopentaose I can also regulate intestinal microbiota to affect immune system development.

HY-101402

Cyclo(his-pro) Cyclo(histidyl-proline); Histidylproline diketopiperazine	NF-κB Endogenous Metabolite	Inflammation/Immunology Neurological Disease
Cyclo(his-pro) (Cyclo(histidyl-proline)) is an orally active cyclic dipeptide structurally related to tyreotropin-releasing hormone. Cyclo(his-pro) could inhibit NF-κB nuclear accumulation. Cyclo(his-pro) can cross the brain-blood-barrier and affect diverse inflammatory and stress responses.

HY-P1934

Cyclo(Phe-Pro) Cyclo(phenylalanylprolyl); A-64863	HCV	Infection
Cyclo(Phe-Pro) (Cyclo(phenylalanylprolyl)), a Vibrio vulnificus quorum-sensing molecule, inhibits retinoic acid-inducible gene-I (RIG-I) polyubiquitination, through its specific interaction with RIG-I, to blunt IRF-3 activation and type-I IFN production. Cyclo(Phe-Pro) (Cyclo(phenylalanylprolyl)) enhances susceptibility to hepatitis C virus (HCV), as well as Sendai and influenza viruses.

HY-P1934A

Cyclo(L-Phe-L-Pro)	Fungal IFNAR Reactive Oxygen Species	Cancer Inflammation/Immunology Infection
Cyclo(L-Phe-L-Pro), isolated from Pseudomonas fluorescens and Pseudomonas alcaligenes cell-free culture supernatants is an antifungal cyclic dipeptide. Cyclo(L-Phe-L-Pro) inhibits IFN-β production by interfering with retinoic-acid-inducible gene-I (RIG-I) activation. Cyclo(L-Phe-L-Pro) exhibits free-radical scavenging activity with the IC₅₀ of 24 µM in the DPPH assay.

HY-107738

Guggulsterone Z/E-Guggulsterone	Apoptosis JNK Akt Caspase FXR Autophagy	Cancer
Guggulsterone is a plant sterol derived from the gum resin of the tree Commiphora wightii. Guggulsterone inhibits the growth of a wide variety of tumor cells and induces apoptosis through down regulation of antiapoptotic gene products (IAP1, xIAP, Bfl-1/A1, Bcl-2, cFLIP and survivin), modulation of cell cycle proteins (cyclin D1 and c-Myc), activation of caspases and JNK, inhibition of Akt. Guggulsterone, a farnesoid X receptor (FXR) antagonist, decreases CDCA-induced FXR activation with IC₅₀s of 17 and 15 μM for Z- and E-Guggulsterone, respectively.

HY-P0023A

Cyclo(-RGDfK) TFA	Integrin	Cancer
Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the α_vβ₃ integrin, with an IC₅₀ of 0.94 nM. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface.

HY-107245

Segetalin B
Estrogen Receptor/ERR Metabolic Disease

Segetalin B, a cyclopentapeptide from Vaccaria segetalis, possesses estrogen-like activity.
HY-P0031

Cyclo(RADfK)
Integrin Others

Cyclo(RADfK) is a selective α(v)β(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis.

Segetalin B	Estrogen Receptor/ERR	Metabolic Disease
Segetalin B, a cyclopentapeptide from Vaccaria segetalis, possesses estrogen-like activity.

Cyclo(RADfK)	Integrin	Others
Cyclo(RADfK) is a selective α(v)β(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis.

HY-P0023

Cyclo(-RGDfK)	Integrin	Cancer
Cyclo(-RGDfK) is a potent and selective inhibitor of the α_vβ₃ integrin, with an IC₅₀ of 0.94 nM. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface.

HY-P2300

Cyclo(Arg-Gly-Asp-D-Phe-Cys) Cyclo(RGDfC)	Integrin	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC), a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) can be used in the research of tumors.

HY-126810A

NP213 TFA	Fungal	Infection
NP213 TFA is a rapidly acting, novel, first-in-class synthetic antimicrobial peptide (AMP), has anti-fungal activities. NP213 TFA targets the fungal cytoplasmic membrane and plays it role via membrane perturbation and disruption. NP213 TFA is effective and well-tolerated in resolving nail fungal infections.

HY-126810

NP213	Fungal	Infection
NP213 is a rapidly acting, novel, first-in-class synthetic antimicrobial peptide (AMP), has anti-fungal activities. NP213 targets the fungal cytoplasmic membrane and plays it role via membrane perturbation and disruption. NP213 is effective and well-tolerated in resolving nail fungal infections.

HY-P0231

AZP-531
GHSR Metabolic Disease Endocrinology

AZP-531 is an analogue of unacylated ghrelin designed to improve glycaemic control and reduce weight.

AZP-531	GHSR	Metabolic Disease Endocrinology
AZP-531 is an analogue of unacylated ghrelin designed to improve glycaemic control and reduce weight.

HY-P1201A

Cyclosomatostatin TFA	Somatostatin Receptor	Cancer
Cyclosomatostatin TFA is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin TFA can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells.

HY-P1201

Cyclosomatostatin	Somatostatin Receptor	Cancer
Cyclosomatostatin is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells.

HY-P1613

Cyclo(Arg-Gly-Asp-D-Phe-Val)	Integrin Apoptosis	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Val) is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) can be used for the research of acute myeloid leukemia.

HY-P1613A

Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA	Integrin Apoptosis	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) can be used for the research of acute myeloid leukemia.

HY-P1104A

FC131 TFA
CXCR HIV Infection

FC131 TFA is a CXCR4 antagonist, inhibits [¹²⁵I]-SDF-1 binding to CXCR4, with an IC₅₀ of 4.5 nM. Anti-HIV activity.

FC131 TFA	CXCR HIV	Infection
FC131 TFA is a CXCR4 antagonist, inhibits [¹²⁵I]-SDF-1 binding to CXCR4, with an IC₅₀ of 4.5 nM. Anti-HIV activity.

HY-P3293

Lonodelestat POL6014	Elastase	Inflammation/Immunology
Lonodelestat (POL6014) is a potent, orally active and selective peptide inhibitor of human neutrophil elastase (hNE). Lonodelestat (POL6014) has the potential for the research of cystic fibrosis (CF).

HY-P0227

SHU 9119	Melanocortin Receptor	Metabolic Disease
SHU 9119 is a potent human melanocortin 3 and 4 receptors (MC3/4R) antagonist and a partial MC5R agonist; with IC₅₀ values of 0.23, 0.06, and 0.09 nM for human MC3R, MC4R and MC5R, respectively.

HY-W019721

Cyclosporin D	Nuclear Factor of activated T Cells (NFAT)	Inflammation/Immunology
Cyclosporin D, a metabolite of Cyclosporin A, is a weak immunosuppressant. Cyclosporin D is used as internal standard for quantification of Cyclosporin A. Cyclosporin A is a potent immunosuppressant drug, suppress T cell activation by inhibiting calcineurin and the calcineurin-dependent transcription factors nuclear factor of activated T cells (NFAc).

HY-P1206

CH 275	Somatostatin Receptor	Neurological Disease
CH 275 is a peptide analog of somatostatin and binds preferably to somatostatin receptor 1 (sst₁) with a K_i of 52 nM. CH 275 acts as a potent and selective sst₁ agonist (IC₅₀=30.9 nM) and also displays IC₅₀ values of 345 nM, >1 μM, >10 μM, >10 μM for human sst₃, sst₄, sst₂ and sst₅, respectively. CH 275 can be used for the research of alzheimer’s disease.

HY-P1420

TAT-cyclo-CLLFVY	HIF/HIF Prolyl-Hydroxylase	Cancer
TAT-cyclo-CLLFVY is a cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. TAT-cyclo-CLLFVY disrupts HIF-1α/HIF-1β protein-protein interaction with an IC₅₀ of 1.3 μM.

HY-P1420A

TAT-cyclo-CLLFVY TFA	HIF/HIF Prolyl-Hydroxylase	Cancer
TAT-cyclo-CLLFVY TFA is a cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. TAT-cyclo-CLLFVY TFA disrupts HIF-1α/HIF-1β protein-protein interaction with an IC₅₀ of 1.3 μM.

HY-16381A

Pasireotide acetate SOM230 acetate	Somatostatin Receptor	Cancer Endocrinology
Pasireotide (SOM230) acetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pK_i=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide acetate can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide acetate also exhibits antisecretory, antiproliferative, and proapoptotic activity.

HY-P1674A

Murepavadin TFA POL7080 TFA	Bacterial Antibiotic	Infection
Murepavadin (POL7080) (TFA), a 14-amino-acid cyclic peptide, is a highly potent, specific antibiotic. Murepavadin exhibits a potent antimicrobial activity for P. aeruginosa with MIC₅₀ and MIC₉₀ values both of 0.12 mg/L. Murepavadin also can target the lipopolysaccharide transport portin D. Murepavadin can be used for the research of bacterial resistance.

HY-P1674

Murepavadin POL7080	Bacterial Antibiotic	Infection
Murepavadin (POL7080), a 14-amino-acid cyclic peptide, is a highly potent, specific antibiotic. Murepavadin exhibits a potent antimicrobial activity for P. aeruginosa with both MIC₅₀ and MIC₉₀ values of 0.12 mg/L. Murepavadin also can target the lipopolysaccharide transport portin D. Murepavadin can be used for the research of bacterial resistance.

HY-16381

Pasireotide SOM230	Somatostatin Receptor	Cancer Endocrinology
Pasireotide (SOM230), a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pK_i=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide also exhibits antisecretory, antiproliferative, and proapoptotic activity.

HY-P1980

A-71915 TFA	Apoptosis	Metabolic Disease
A-71915 (TFA) is a selective inhibitor of ANP receptor (atrial natriuretic peptide-receptor), induces apoptosis and decreases insulin secretion in RINm5F pancreatic β-cells.

HY-P1682A

Balixafortide TFA POL6326 TFA	CXCR Arrestin	Cancer
Balixafortide TFA (POL6326 TFA) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC₅₀ < 10 nM. Balixafortide TFA shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide TFA blocks β-arrestin recruitment and calcium flux with IC₅₀s < 10 nM. Balixafortide TFA is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects.

HY-P1682

Balixafortide POL6326	CXCR Arrestin	Cancer
Balixafortide (POL6326) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC₅₀ < 10 nM. Balixafortide shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide blocks β-arrestin recruitment and calcium flux with IC₅₀s < 10 nM. Balixafortide is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects.

HY-P1045A

187-1, N-WASP inhibitor TFA	Arp2/3 Complex	Others
187-1, N-WASP inhibitor TFA, a 14-aa cyclic peptide, is an allosteric neural Wiskott-Aldrich syndrome protein (N-WASP) inhibitor. 187-1, N-WASP inhibitor TFA potently inhibits actin assembly induced by phosphatidylinositol 4,5-bisphosphate (PIP2) with an IC₅₀ of 2 μM. 187-1, N-WASP inhibitor TFA prevents the activation of Arp2/3 complex by N-WASP by stabilizing the autoinhibited state of the protein.

HY-P1045

187-1, N-WASP inhibitor	Arp2/3 Complex	Others
187-1, N-WASP inhibitor, a 14-aa cyclic peptide, is an allosteric neural Wiskott-Aldrich syndrome protein (N-WASP) inhibitor. 187-1, N-WASP inhibitor potently inhibits actin assembly induced by phosphatidylinositol 4,5-bisphosphate (PIP2) with an IC₅₀ of 2 μM. 187-1, N-WASP inhibitor prevents the activation of Arp2/3 complex by N-WASP by stabilizing the autoinhibited state of the protein.

HY-P3066

SKF 100398 d(CH2)5Tyr(Et)VAVP	Vasopressin Receptor	Metabolic Disease
SKF 100398 (d(CH2)5Tyr(Et)VAVP), an arginine vasopressin (AVP) analogue, is a specific antagonist of the antidiuretic effect of exogenous and endogenous AVP.

HY-P1122

Cyclosporin H	Formyl Peptide Receptor (FPR)	Infection Inflammation/Immunology
Cyclosporin H is a selective and potent inhibitor of FPR-1 (formyl peptide receptor 1). Cyclosporin H, a viral transduction enhancer, increases lentiviral transduction up to 10-fold in human cord blood-derived hematopoietic stem and progenitor cells (HSPCs). Cyclosporin H displays an additive effect when combined with Rapamycin (HY-10219) or Prostaglandin E2 (HY-101952). Cyclosporin H lacks immunosuppressant activity of Cyclosporin A.

HY-P3440

WL12	PD-1/PD-L1	Cancer
WL12 is a specifically targeting programmed death ligand 1 (PD-L1) binding peptide. WL12 can be radiolabeled by different radionuclides, generating radiotracers, which can assess the tumor PD-L1 expression.

Cat. No.	Product Name	Target	Research Area

HY-P3193

Cyclic nona-L-arginine TFA
Peptides Others

Cyclic nona-L-arginine TFA, a nonaarginine peptide used for drug delivery, translocates faster than their linear counterparts.

HY-P3193A

Cyclic nona-L-arginine hydrochloride	Peptides	Others
Cyclic nona-L-arginine hydrochloride, a nonaarginine peptide used for drug delivery, translocates faster than their linear counterparts.

HY-P1934

Cyclo(Phe-Pro) Cyclo(phenylalanylprolyl); A-64863	HCV	Infection
Cyclo(Phe-Pro) (Cyclo(phenylalanylprolyl)), a Vibrio vulnificus quorum-sensing molecule, inhibits retinoic acid-inducible gene-I (RIG-I) polyubiquitination, through its specific interaction with RIG-I, to blunt IRF-3 activation and type-I IFN production. Cyclo(Phe-Pro) (Cyclo(phenylalanylprolyl)) enhances susceptibility to hepatitis C virus (HCV), as well as Sendai and influenza viruses.

HY-P1934A

Cyclo(L-Phe-L-Pro)	Fungal IFNAR Reactive Oxygen Species	Cancer Inflammation/Immunology Infection
Cyclo(L-Phe-L-Pro), isolated from Pseudomonas fluorescens and Pseudomonas alcaligenes cell-free culture supernatants is an antifungal cyclic dipeptide. Cyclo(L-Phe-L-Pro) inhibits IFN-β production by interfering with retinoic-acid-inducible gene-I (RIG-I) activation. Cyclo(L-Phe-L-Pro) exhibits free-radical scavenging activity with the IC₅₀ of 24 µM in the DPPH assay.

HY-P0023A

Cyclo(-RGDfK) TFA	Integrin	Cancer
Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the α_vβ₃ integrin, with an IC₅₀ of 0.94 nM. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface.

HY-107245

Segetalin B
Estrogen Receptor/ERR Metabolic Disease

Segetalin B, a cyclopentapeptide from Vaccaria segetalis, possesses estrogen-like activity.
HY-P0031

Cyclo(RADfK)
Integrin Others

Cyclo(RADfK) is a selective α(v)β(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis.

HY-P0023

Cyclo(-RGDfK)	Integrin	Cancer
Cyclo(-RGDfK) is a potent and selective inhibitor of the α_vβ₃ integrin, with an IC₅₀ of 0.94 nM. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface.

HY-P2300

Cyclo(Arg-Gly-Asp-D-Phe-Cys) Cyclo(RGDfC)	Integrin	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC), a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) can be used in the research of tumors.

HY-126810A

NP213 TFA	Fungal	Infection
NP213 TFA is a rapidly acting, novel, first-in-class synthetic antimicrobial peptide (AMP), has anti-fungal activities. NP213 TFA targets the fungal cytoplasmic membrane and plays it role via membrane perturbation and disruption. NP213 TFA is effective and well-tolerated in resolving nail fungal infections.

HY-P0231

AZP-531
GHSR Metabolic Disease Endocrinology

AZP-531 is an analogue of unacylated ghrelin designed to improve glycaemic control and reduce weight.

HY-P4047

Cyclo(RGDfK(Mal))	Peptides	Others
Cyclo(RGDfK(Mal)) is a pentapeptide. Cyclo(RGDfK(Mal)) improves the attachment and infiltration of human pluripotent stem cells. Cyclo(RGDfK(Mal)) can be used for 3D stem cell culture and expansion.

HY-P1201A

Cyclosomatostatin TFA	Somatostatin Receptor	Cancer
Cyclosomatostatin TFA is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin TFA can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells.

HY-P1201

Cyclosomatostatin	Somatostatin Receptor	Cancer
Cyclosomatostatin is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells.

HY-P1613

Cyclo(Arg-Gly-Asp-D-Phe-Val)	Integrin Apoptosis	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Val) is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) can be used for the research of acute myeloid leukemia.

HY-P1613A

Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA	Integrin Apoptosis	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) can be used for the research of acute myeloid leukemia.

HY-139741

cyclo(Phe-Ala-Gly-Arg-Arg-Arg-Gly-AEEAc)	Peptides	Others
cyclo(Phe-Ala-Gly-Arg-Arg-Arg-Gly-AEEAc) provides an avenue for developing a nonhormonal male contraceptive by blocking of GRTH/DDX25 phosphorylation.

HY-P3958

BIM-23027	Peptides	Neurological Disease
BIM-23027 is a selective agonist of sst₂ receptor (EC₅₀=0.32 nM), with similar effect to somatostatin (SRIF), a cyclic tetradecapeptide. BIM-23027 stimulates dopamine release, which is mediated by a Glu-dependent mechanism.

HY-P1104A

FC131 TFA
CXCR HIV Infection

FC131 TFA is a CXCR4 antagonist, inhibits [¹²⁵I]-SDF-1 binding to CXCR4, with an IC₅₀ of 4.5 nM. Anti-HIV activity.

HY-P3293

Lonodelestat POL6014	Elastase	Inflammation/Immunology
Lonodelestat (POL6014) is a potent, orally active and selective peptide inhibitor of human neutrophil elastase (hNE). Lonodelestat (POL6014) has the potential for the research of cystic fibrosis (CF).

HY-P0227

SHU 9119	Melanocortin Receptor	Metabolic Disease
SHU 9119 is a potent human melanocortin 3 and 4 receptors (MC3/4R) antagonist and a partial MC5R agonist; with IC₅₀ values of 0.23, 0.06, and 0.09 nM for human MC3R, MC4R and MC5R, respectively.

HY-W019721

Cyclosporin D	Nuclear Factor of activated T Cells (NFAT)	Inflammation/Immunology
Cyclosporin D, a metabolite of Cyclosporin A, is a weak immunosuppressant. Cyclosporin D is used as internal standard for quantification of Cyclosporin A. Cyclosporin A is a potent immunosuppressant drug, suppress T cell activation by inhibiting calcineurin and the calcineurin-dependent transcription factors nuclear factor of activated T cells (NFAc).

HY-P1206

CH 275	Somatostatin Receptor	Neurological Disease
CH 275 is a peptide analog of somatostatin and binds preferably to somatostatin receptor 1 (sst₁) with a K_i of 52 nM. CH 275 acts as a potent and selective sst₁ agonist (IC₅₀=30.9 nM) and also displays IC₅₀ values of 345 nM, >1 μM, >10 μM, >10 μM for human sst₃, sst₄, sst₂ and sst₅, respectively. CH 275 can be used for the research of alzheimer’s disease.

HY-P2269

MAIT-203	Peptides	Cancer
MAIT-203, a cyclopentyalanin-derived peptidomimetic, potently inhibits the interaction of adenomatous polyposis coli (APC) and Asef (RhoGEF4), but not APC-Sam68 or APC-striatin interactions. MAIT-203 binds APC-ARM with a K_i of 0.015 μM and a K_d of 0.036 μM. MAIT-203 significantly represses the migration and invasion of colorectal cancer cells.

HY-P0257

Astressin
Peptides Neurological Disease

Astressin is a potent corticotropin releasing factor (CRF) antagonist.

HY-P1420

TAT-cyclo-CLLFVY	HIF/HIF Prolyl-Hydroxylase	Cancer
TAT-cyclo-CLLFVY is a cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. TAT-cyclo-CLLFVY disrupts HIF-1α/HIF-1β protein-protein interaction with an IC₅₀ of 1.3 μM.

HY-P1420A

TAT-cyclo-CLLFVY TFA	HIF/HIF Prolyl-Hydroxylase	Cancer
TAT-cyclo-CLLFVY TFA is a cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. TAT-cyclo-CLLFVY TFA disrupts HIF-1α/HIF-1β protein-protein interaction with an IC₅₀ of 1.3 μM.

HY-16381A

Pasireotide acetate SOM230 acetate	Somatostatin Receptor	Cancer Endocrinology
Pasireotide (SOM230) acetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pK_i=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide acetate can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide acetate also exhibits antisecretory, antiproliferative, and proapoptotic activity.

HY-P1674A

Murepavadin TFA POL7080 TFA	Bacterial Antibiotic	Infection
Murepavadin (POL7080) (TFA), a 14-amino-acid cyclic peptide, is a highly potent, specific antibiotic. Murepavadin exhibits a potent antimicrobial activity for P. aeruginosa with MIC₅₀ and MIC₉₀ values both of 0.12 mg/L. Murepavadin also can target the lipopolysaccharide transport portin D. Murepavadin can be used for the research of bacterial resistance.

HY-P1674

Murepavadin POL7080	Bacterial Antibiotic	Infection
Murepavadin (POL7080), a 14-amino-acid cyclic peptide, is a highly potent, specific antibiotic. Murepavadin exhibits a potent antimicrobial activity for P. aeruginosa with both MIC₅₀ and MIC₉₀ values of 0.12 mg/L. Murepavadin also can target the lipopolysaccharide transport portin D. Murepavadin can be used for the research of bacterial resistance.

HY-16381

Pasireotide SOM230	Somatostatin Receptor	Cancer Endocrinology
Pasireotide (SOM230), a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pK_i=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide also exhibits antisecretory, antiproliferative, and proapoptotic activity.

HY-P1980

A-71915 TFA	Apoptosis	Metabolic Disease
A-71915 (TFA) is a selective inhibitor of ANP receptor (atrial natriuretic peptide-receptor), induces apoptosis and decreases insulin secretion in RINm5F pancreatic β-cells.

HY-P1682A

Balixafortide TFA POL6326 TFA	CXCR Arrestin	Cancer
Balixafortide TFA (POL6326 TFA) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC₅₀ < 10 nM. Balixafortide TFA shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide TFA blocks β-arrestin recruitment and calcium flux with IC₅₀s < 10 nM. Balixafortide TFA is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects.

HY-P1682

Balixafortide POL6326	CXCR Arrestin	Cancer
Balixafortide (POL6326) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC₅₀ < 10 nM. Balixafortide shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide blocks β-arrestin recruitment and calcium flux with IC₅₀s < 10 nM. Balixafortide is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects.

HY-P1045A

187-1, N-WASP inhibitor TFA	Arp2/3 Complex	Others
187-1, N-WASP inhibitor TFA, a 14-aa cyclic peptide, is an allosteric neural Wiskott-Aldrich syndrome protein (N-WASP) inhibitor. 187-1, N-WASP inhibitor TFA potently inhibits actin assembly induced by phosphatidylinositol 4,5-bisphosphate (PIP2) with an IC₅₀ of 2 μM. 187-1, N-WASP inhibitor TFA prevents the activation of Arp2/3 complex by N-WASP by stabilizing the autoinhibited state of the protein.

HY-P1045

187-1, N-WASP inhibitor	Arp2/3 Complex	Others
187-1, N-WASP inhibitor, a 14-aa cyclic peptide, is an allosteric neural Wiskott-Aldrich syndrome protein (N-WASP) inhibitor. 187-1, N-WASP inhibitor potently inhibits actin assembly induced by phosphatidylinositol 4,5-bisphosphate (PIP2) with an IC₅₀ of 2 μM. 187-1, N-WASP inhibitor prevents the activation of Arp2/3 complex by N-WASP by stabilizing the autoinhibited state of the protein.

HY-P3066

SKF 100398 d(CH2)5Tyr(Et)VAVP	Vasopressin Receptor	Metabolic Disease
SKF 100398 (d(CH2)5Tyr(Et)VAVP), an arginine vasopressin (AVP) analogue, is a specific antagonist of the antidiuretic effect of exogenous and endogenous AVP.

HY-P1122

Cyclosporin H	Formyl Peptide Receptor (FPR)	Infection Inflammation/Immunology
Cyclosporin H is a selective and potent inhibitor of FPR-1 (formyl peptide receptor 1). Cyclosporin H, a viral transduction enhancer, increases lentiviral transduction up to 10-fold in human cord blood-derived hematopoietic stem and progenitor cells (HSPCs). Cyclosporin H displays an additive effect when combined with Rapamycin (HY-10219) or Prostaglandin E2 (HY-101952). Cyclosporin H lacks immunosuppressant activity of Cyclosporin A.

HY-P3440

WL12	PD-1/PD-L1	Cancer
WL12 is a specifically targeting programmed death ligand 1 (PD-L1) binding peptide. WL12 can be radiolabeled by different radionuclides, generating radiotracers, which can assess the tumor PD-L1 expression.

Cat. No.	Product Name	Target	Category

HY-N0417

Cucurbitacin E α-Elaterin; α-Elaterine	CDK Autophagy	Triterpenes Terpenoids Structural Classification Plants Source classification Cucurbitaceae Disease Research Fields Cancer Classification of Application Fields
Cucurbitacin E is a natural compound which from Cucurbitaceae plants. Cucurbitacin E significantly suppresses the activity of the cyclin B1/CDC2 complex.

HY-N6954

Garcinone C	ATM/ATR STAT CDK	Phenols Xanthones Polyphenols Disease Research Fields Cancer Classification of Application Fields Source classification Plants other families Guttiferae Garcinia oblongifolia Champ. ex Benth.
Garcinone C, a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia that is used as an anti-inflammatory, astringency and granulation-promoting medicine, and has potential cytotoxic effects on certain cancers. Garcinone C stimulates the expression levels of ATR and *4E-BP1, while efficiently inhibiting the expression levels of cyclin* B1, cyclin D1, cyclin E2, cdc2, Stat3 and CDK7. Garcinone C significantly inhibits cell viability of the human Nasopharyngeal carcinoma (NPC) cell lines CNE1, CNE2, HK1 and HONE1 in a time‑ and dose‑dependent manner.

HY-133537

Hygrolidin	Antibiotic Fungal ADC Cytotoxin	Antibiotics Structural Classification Macrolide Antibiotics Microorganisms Source classification Infection Disease Research Fields Classification of Application Fields
Hygrolidin is a 16-membered macrolide antibiotic produced by Streptomyces hygroscopicus D-1166. Hygrolidin has anti-fungus activity against Valsa ceratosperma. Hygrolidin induces p21 expression and abrogates cell cycle progression at G1 and S phases. Hygrolidin has antitumor activity.

HY-W019806

Lacto-N-fucopentaose I LNFP I	Endogenous Metabolite CDK Reactive Oxygen Species Apoptosis Enterovirus Bacterial	Saccharides Polysaccharides Structural Classification Natural Products Animals Inflammation/Immunology Infection Disease Research Fields Classification of Application Fields
Lacto-N-fucopentaose I (LNFPI) is a human milk oligosaccharide (HMO), possessing antiviral and antibacterial activity. Lacto-N-fucopentaose I can reduce capsid protein VP1 to block virus adsorption, promote CDK2 and reduce cyclin E to recover cell cycle S phase block. Lacto-N-fucopentaose I inhibits ROS production and apoptosis in virus-infected cells. Lacto-N-fucopentaose I can also regulate intestinal microbiota to affect immune system development.

HY-101402

Cyclo(his-pro) Cyclo(histidyl-proline); Histidylproline diketopiperazine	NF-κB Endogenous Metabolite	Natural Products Source classification Endogenous metabolite
Cyclo(his-pro) (Cyclo(histidyl-proline)) is an orally active cyclic dipeptide structurally related to tyreotropin-releasing hormone. Cyclo(his-pro) could inhibit NF-κB nuclear accumulation. Cyclo(his-pro) can cross the brain-blood-barrier and affect diverse inflammatory and stress responses.

HY-P1934A

Cyclo(L-Phe-L-Pro)	Fungal IFNAR Reactive Oxygen Species	Structural Classification Natural Products
Cyclo(L-Phe-L-Pro), isolated from Pseudomonas fluorescens and Pseudomonas alcaligenes cell-free culture supernatants is an antifungal cyclic dipeptide. Cyclo(L-Phe-L-Pro) inhibits IFN-β production by interfering with retinoic-acid-inducible gene-I (RIG-I) activation. Cyclo(L-Phe-L-Pro) exhibits free-radical scavenging activity with the IC₅₀ of 24 µM in the DPPH assay.

HY-107738

Guggulsterone Z/E-Guggulsterone	Apoptosis JNK Akt Caspase FXR Autophagy	Triterpenes Structural Classification Terpenoids Burseraceae Plants Commiphora wightii Disease Research Fields Cancer Classification of Application Fields
Guggulsterone is a plant sterol derived from the gum resin of the tree Commiphora wightii. Guggulsterone inhibits the growth of a wide variety of tumor cells and induces apoptosis through down regulation of antiapoptotic gene products (IAP1, xIAP, Bfl-1/A1, Bcl-2, cFLIP and survivin), modulation of cell cycle proteins (cyclin D1 and c-Myc), activation of caspases and JNK, inhibition of Akt. Guggulsterone, a farnesoid X receptor (FXR) antagonist, decreases CDCA-induced FXR activation with IC₅₀s of 17 and 15 μM for Z- and E-Guggulsterone, respectively.

HY-107245

Segetalin B	Estrogen Receptor/ERR	Cyclopeptides Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Plants Caryophyllaceae Vaccaria segetalis (Neck.) Garcke
Segetalin B, a cyclopentapeptide from Vaccaria segetalis, possesses estrogen-like activity.

HY-W019721

Cyclosporin D	Nuclear Factor of activated T Cells (NFAT)	Natural Products Inflammation/Immunology Disease Research Fields Classification of Application Fields Source classification Microorganisms
Cyclosporin D, a metabolite of Cyclosporin A, is a weak immunosuppressant. Cyclosporin D is used as internal standard for quantification of Cyclosporin A. Cyclosporin A is a potent immunosuppressant drug, suppress T cell activation by inhibiting calcineurin and the calcineurin-dependent transcription factors nuclear factor of activated T cells (NFAc).

Species:	Human (6) Mouse (1)
Tag:	His (6) SUMO (1) Tag Free (1) GST (3)
Source:	Sf9 insect cells (5) E. coli (2)

Cat. No.	Product Name	Species	Source

HY-P74214

Cyclin E Protein, Human (sf9)
CCNE; CCNE1; cyclin E1; G1/S-specific cyclin-E1
Human Sf9 insect cells
HY-P74213

Cyclin E Protein, Human (sf9, His)
CCNE; CCNE1; cyclin E1; G1/S-specific cyclin-E1
Human Sf9 insect cells
HY-P72963

Cyclin E Protein, Human (SF9, His-GST)
CCNE; CCNE1; CCNEcyclin Es; cyclin E1; G1/S-specific cyclin-E1
Human Sf9 insect cells
HY-P72964

Cyclin E Protein, Mouse (SF9, His-GST)
CCNE; CCNE1; CCNEcyclin Es; cyclin E1; G1/S-specific cyclin-E1
Mouse Sf9 insect cells
HY-P74257

CDK1-CCNE1 Heterodimer Protein, Human (sf9, His-GST)
cyclin-dependent kinase 1; CDK1; CDC2; G1/S-specific cyclin-E1; CCNE1
Human Sf9 insect cells

HY-P71531

SKP2 Protein, Human (His-SUMO) CDK2/cyclin A associated protein p45; cyclin A/CDK2 associated protein p45; cyclin-A/CDK2-associated protein p45; F box protein Skp2; F box/LRR repeat protein 1; F-box protein Skp2; F-box/LRR-repeat protein 1; FBL 1; FBL1; FBXL 1; FBXL1; FLB 1; FLB1; MGC1366; p45; p45skp2; S phase kinase associated protein 2 (p45); S phase kinase associated protein 2; S-phase kinase-associated protein 2; S-phase kinase-associated protein 2 E3 ubiquitin protein ligase; SKP 2; Skp2; SKP2_HUMAN	Human	E. coli

HY-P72119

CCND1 Protein, Human (His) AI327039; B cell leukemia 1; B-cell lymphoma 1 protein; BCL 1; BCL-1; BCL-1 oncogene; BCL1; BCL1 oncogene; ccnd1; CCND1/FSTL3 fusion gene; CCND1/FSTL3 fusion gene; included; CCND1/IGHG1 fusion gene; CCND1/IGLC1 fusion gene; CCND1_HUMAN; cD1; Cyl 1; D11S287E; G1/S specific cyclin D1; G1/S-specific cyclin-D1; PRAD1; PRAD1 oncogene; U21B31	Human	E. coli

cyclin E

Inhibitors & Agonists

Peptides

NaturalProducts

Recombinant Proteins

Natural
Products